Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quebec Precious Metals Corporation V.QPM

Alternate Symbol(s):  CJCFF

Quebec Precious Metals Corporation is a Canada-based gold explorer with a land position in the prospective Eeyou Istchee James Bay territory, Quebec, near Newmont Corporation’s Eleonore gold mine. The Company’s flagship project is the Sakami project with significant grades and drill-ready targets. The Sakami project is located in the Eeyou Istchee James Bay territory of northern Quebec. The project consists of approximately 281 claims covering a total area of 143 square kilometers. Its 100% owned Elmer East project is located along trend from the recent Patwon prospect gold discovery made by Azimut Exploration Inc. The project has gold potential totaling about 929 claims (488.4 square kilometers) and includes the adjacent Annabelle block, and the Opinaca Gold West block. Its 100% owned Cheechoo-Eleonore Trend project comprises about 128 claims (66.4 square kilometers) and is adjacent to the northwest to the Company’s Sakami project. It also owns various non-core assets.


TSXV:QPM - Post by User

Post by JABombardieron Jan 18, 2005 3:31pm
327 Views
Post# 8449178

Labopharm (DDS)Tramadol...Approval..Canaccord

Labopharm (DDS)Tramadol...Approval..CanaccordLabopharm "buy" Tuesday, January 18, 2005 4:03:41 AM ET Canaccord Capital NEW YORK, January 18 (newratings.com) - Analysts at Canaccord Capital reiterate their "buy" rating on Labopharm Inc (DDS.TOR). The target price is set to C$5.50. Most popular stories: Bayer upgraded to "buy" 12:09pm JAMDAT Mobile upgraded to "overweight" 12:14pm May Department Stores upgraded to "overweight" 12:41pm eBay "neutral weight" 12:36pm Sez upgraded to "buy" 12:06pm more... In a research note published yesterday, the analysts mention that the company's once-a-day tramadol drug for the treatment of moderate to severe pain has been approved by the French authorities. Labopharm, in partnership with Sanofi-Aventis, intends to launch the drug in the fast-growing European market in 4Q05, the analysts say. The company is to initiate the Mutual Recognition Procedure (MRP) in order to streamline regulatory approval in other European Union countries, Canaccord Capital adds.
Bullboard Posts